{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:29:51Z","timestamp":1740130191042,"version":"3.37.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Taiwan Ministry of Health"},{"name":"Welfare Clinical Trial Center","award":["MOHW109-TDU-B-212-114004"],"award-info":[{"award-number":["MOHW109-TDU-B-212-114004"]}]},{"name":"MOST Clinical Trial Consortium for Stroke","award":["MOST 109-2321-B-039-002","Tseng-Lien Lin Foundation"],"award-info":[{"award-number":["MOST 109-2321-B-039-002","Tseng-Lien Lin Foundation"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Men are more likely to develop benign prostatic hyperplasia (BPH) and gout as they age. However, the role of alpha-1-adrenergic antagonists, the medication for BPH, in the development of gout is uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the effect of alpha-1-adrenergic antagonist use on the risk of developing gout in BPH patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data of patients with newly diagnosed BPH were retrieved from Taiwan\u2019s 2000\u20132013 National Health Insurance Research Database (total number: 15,390 patients; 7,695 patients in each cohort). Propensity score matching was conducted according to age, comorbidities, medication history for cohorts that received or did not receive alpha-1-adrenergic antagonists. Hazard ratios (HRs) were assessed for gout development using Cox proportional hazards regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Use of alpha-1-adrenergic antagonists was not associated with gout development in BPH patients (HR = 0.92; 95% confidence interval [CI], 0.78\u20131.10; P = 0.35). However, after stratification according to the average number of days of alpha-1-adrenergic antagonist use per year, patients with an average of &amp;gt;300 days had a significantly higher risk of gout development than patients who did not receive alpha-1-adrenergic antagonists (adjusted HR = 1.57; 95% CI, 1.25\u20131.97; P &amp;lt; 0.001). Patients with more days of medication use per year had a higher risk of gout development than those with fewer days of medication use (P &amp;lt; 0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients who received more doses of alpha-1-adrenergic antagonists per year had a higher risk of developing gout. A causal proof of the role of alpha-1-adrenergic antagonists use in gout development should be analysed in future studies designed as double blind randomized controlled trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/fampra\/cmab163","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T12:09:03Z","timestamp":1637410143000},"page":"426-431","source":"Crossref","is-referenced-by-count":1,"title":["Association of alpha-1-adrenergic antagonist use with the risk of gout development in benign prostatic hyperplasia patients: a population-based cohort study"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-3103","authenticated-orcid":false,"given":"Wei-Hung","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Hualien , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-4938","authenticated-orcid":false,"given":"Jung-Nien","family":"Lai","sequence":"additional","affiliation":[{"name":"School of Chinese Medicine, College of Chinese Medicine, China Medical University , Taichung , Taiwan"},{"name":"Department of Chinese Medicine, China Medical University Hospital , Taichung , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9926-3668","authenticated-orcid":false,"given":"Cheng-Li","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Chinese Medicine, College of Chinese Medicine, China Medical University , Taichung , Taiwan"},{"name":"Management Office for Health Data (DryLab), Clinical Trial Center (CTC), China Medical University Hospital , Taichung , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3324-0962","authenticated-orcid":false,"given":"Ching-Hui","family":"Loh","sequence":"additional","affiliation":[{"name":"School of Medicine, Tzu Chi University , Hualien , Taiwan"},{"name":"Center for Aging and Health, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Hualien , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-653X","authenticated-orcid":false,"given":"Huei-Kai","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Hualien , Taiwan"},{"name":"Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Hualien , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4445-8729","authenticated-orcid":false,"given":"Liang-Kai","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Hualien , Taiwan"},{"name":"Center for Preventive Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Hualien , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,29]]},"reference":[{"key":"2022053120412943300_CIT0001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000052401","article-title":"How do symptoms indicative of BPH progress in real life practice? The UK experience.","volume":"38","author":"Clifford","year":"2000","journal-title":"Eur Urol"},{"issue":"3","key":"2022053120412943300_CIT0002","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age.","volume":"132","author":"Berry","year":"1984","journal-title":"J Urol"},{"issue":"4","key":"2022053120412943300_CIT0003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11884-010-0067-2","article-title":"Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors.","volume":"5","author":"Parsons","year":"2010","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"2022053120412943300_CIT0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","article-title":"Epidemiology and management of gout in Taiwan: a nationwide population study.","volume":"17","author":"Kuo","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"2022053120412943300_CIT0005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors.","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"2022053120412943300_CIT0006","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"2022053120412943300_CIT0007","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/acr.20232","article-title":"High prevalence of gouty arthritis among the Hmong population in Minnesota.","volume":"62","author":"Portis","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"2022053120412943300_CIT0008","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2022053120412943300_CIT0009","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population.","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"issue":"4","key":"2022053120412943300_CIT0010","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3899\/jrheum.170806","article-title":"The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years.","volume":"45","author":"Elfishawi","year":"2018","journal-title":"J Rheumatol"},{"issue":"4","key":"2022053120412943300_CIT0011","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1464-410X.2007.07061.x","article-title":"The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.","volume":"100","author":"Roehrborn","year":"2007","journal-title":"BJU Int"},{"key":"2022053120412943300_CIT0012","first-page":"S99","article-title":"An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia.","volume":"12","author":"Black","year":"2006","journal-title":"Am J Manag Care"},{"issue":"12","key":"2022053120412943300_CIT0013","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1055\/s-0042-113183","article-title":"Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: cross-sectional cohort study.","volume":"66","author":"Ueno","year":"2016","journal-title":"Drug Res"},{"article-title":"Performing a 1: N case-control match on propensity score.","year":"2004","author":"Parsons","key":"2022053120412943300_CIT0014"},{"key":"2022053120412943300_CIT0015","first-page":"345","article-title":"Evaluation of serum uric acid\/inorganic phosphate ratio in prostate disorders and healthy controls.","volume":"5","author":"Sudha","year":"2014","journal-title":"Int J Biomed Adv Res"},{"issue":"2","key":"2022053120412943300_CIT0016","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41391-018-0047-8","article-title":"Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study.","volume":"21","author":"Li","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"2022053120412943300_CIT0017","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41391-017-0031-8","article-title":"Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.","volume":"21","author":"Kukko","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2022053120412943300_CIT0018","first-page":"135","article-title":"Adrenoceptors in the kidney: localization and pharmacology.","volume":"9","author":"Struyker-Boudier","year":"1987","journal-title":"Clin Exp Hypertens A"}],"container-title":["Family Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/39\/3\/426\/43887029\/cmab163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/39\/3\/426\/43887029\/cmab163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T20:47:13Z","timestamp":1654030033000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/fampra\/article\/39\/3\/426\/6488390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,29]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,12,29]]},"published-print":{"date-parts":[[2022,5,28]]}},"URL":"https:\/\/doi.org\/10.1093\/fampra\/cmab163","relation":{},"ISSN":["1460-2229"],"issn-type":[{"type":"electronic","value":"1460-2229"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,12,29]]}}}